stockportfolio.pro
IQV vs MRNA: Which Stock Is the Better Buy?
IQVIA Holdings Inc. and Moderna, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — IQV vs MRNA, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| IQVIA Holdings Inc. (IQV) | Moderna, Inc. (MRNA) | |
|---|---|---|
| Market cap | $34.6B | $31.6B |
| Revenue (latest FY) | $16.31B | $1.94B |
| Net income (latest FY) | $1.36B | $-2.82B |
| Revenue growth (5y CAGR) | 7.5% | 19.3% |
| Net margin | 8.3% | -145.2% |
| Return on equity | 20.9% | -32.6% |
| P/E ratio | 25.7 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 2 |
| Positive free cash flow | Yes | No |
See the full IQV vs MRNA breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open IQV's full financials → Open MRNA's full financials →More comparisons
Frequently asked questions
Which is bigger, IQV or MRNA?
IQVIA Holdings Inc. is larger by market capitalization — $34.6B versus $31.6B.
Which grows faster, IQV or MRNA?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus 7.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.